More Articles


Artificial Intelligence: The Counter-Argument

Adam Chapman, (Jun 7, 2018)

AI is being touted as the doctor’s new lifeline — we put this proposition to a skeptical doctor.

Sizing Up Pharma’s Tech Maturity

Andrew Stone, (Jun 1, 2018)

Amateurs or aficionados? We get an expert appraisal of the industry’s tech proficiency
Access and Evidence

The Naked Truth About Outcomes-Based Pricing

Ross Davies, (May 22, 2018)

Hype around outcomes-based contracts has been doing the rounds for some time now, but is pharma delivering the goods?
Patients and Medical

Pharma, Stop Flummoxing Patients

Danielle Barron, (May 15, 2018)

Efforts to empower patients are undermined by bamboozling medical information. Is there a straight-forward solution?

Leadership In Japan

Ross Davies, (May 11, 2018)

In the face of new drug pricing reforms, the need to nurture strong leadership is imperative, but not without its challenges.

How To Attract Investors

Ross Davies, (May 4, 2018)

The precarious climate in the US might have spooked some pharma investors – but others are looking to targeted therapies to get more bang for their buck.

How Well Do You Know Your HCP?

Adam Chapman, (May 3, 2018)

Machine learning is a boon for customer engagement. How can pharma best use it?

Achieving Success in Emerging Markets

Andrew Lane, (Apr 21, 2018)

Patients and doctors in emerging markets want more than just high-quality medicines, says Andrew Lane from Abbott
Patients and Medical

Could Behavioral Science Crack Non-Adherence?

Katie Osborne, (Apr 19, 2018)

The industry is looking to the field of psychology to answer one of its most protracted problems
Access and Evidence

Japan’s Perilous New Pricing Policy

Ross Davies, (Apr 13, 2018)

The introduction of a new drug pricing reform in Japan has pharma up in arms. Are their fears justified?